Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine and Low Dose Cytarabine in Older Patients with AML and High-Risk MDS
NCT01272245Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2011
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
Phase 2, open-label trial of homoharringtonine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission at 4 months. Started Jul 2011; status: completed.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01272245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01272245.